307 related articles for article (PubMed ID: 30543165)
1. Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics.
Garcia SN; Guedes RC; Marques MM
Curr Med Chem; 2019; 26(41):7285-7322. PubMed ID: 30543165
[TBL] [Abstract][Full Text] [Related]
2. Linker residues regulate the activity and stability of hexokinase 2, a promising anticancer target.
Ferreira JC; Khrbtli AR; Shetler CL; Mansoor S; Ali L; Sensoy O; Rabeh WM
J Biol Chem; 2021; 296():100071. PubMed ID: 33187984
[TBL] [Abstract][Full Text] [Related]
3. Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells.
Kudryavtseva AV; Fedorova MS; Zhavoronkov A; Moskalev AA; Zasedatelev AS; Dmitriev AA; Sadritdinova AF; Karpova IY; Nyushko KM; Kalinin DV; Volchenko NN; Melnikova NV; Klimina KM; Sidorov DV; Popov AY; Nasedkina TV; Kaprin AD; Alekseev BY; Krasnov GS; Snezhkina AV
BMC Genet; 2016 Dec; 17(Suppl 3):156. PubMed ID: 28105937
[TBL] [Abstract][Full Text] [Related]
4. A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers.
Xu S; Herschman HR
Cancer Res; 2019 Dec; 79(23):5907-5914. PubMed ID: 31434645
[TBL] [Abstract][Full Text] [Related]
5. Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis.
Zheng M; Wu C; Yang K; Yang Y; Liu Y; Gao S; Wang Q; Li C; Chen L; Li H
Pharmacol Res; 2021 Feb; 164():105367. PubMed ID: 33307221
[TBL] [Abstract][Full Text] [Related]
6. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
7. Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth.
Liu Y; Murray-Stewart T; Casero RA; Kagiampakis I; Jin L; Zhang J; Wang H; Che Q; Tong H; Ke J; Jiang F; Wang F; Wan X
Int J Oncol; 2017 Jun; 50(6):2011-2023. PubMed ID: 28498475
[TBL] [Abstract][Full Text] [Related]
8. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme.
Wolf A; Agnihotri S; Munoz D; Guha A
Neurobiol Dis; 2011 Oct; 44(1):84-91. PubMed ID: 21726646
[TBL] [Abstract][Full Text] [Related]
9. MiR-216a-5p/Hexokinase 2 axis regulates uveal melanoma growth through modulation of Warburg effect.
Liu Y; Huo Y; Wang D; Tai Y; Li J; Pang D; Zhang Y; Zhao W; Du N; Huang Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):885-892. PubMed ID: 29763606
[TBL] [Abstract][Full Text] [Related]
10. Advances in the Study of Hexokinase 2 (HK2) Inhibitors.
Wang S; Zhuang Y; Xu J; Tong Y; Li X; Dong C
Anticancer Agents Med Chem; 2023; 23(7):736-746. PubMed ID: 36278443
[TBL] [Abstract][Full Text] [Related]
11. MiR-125b-5p suppressed the glycolysis of laryngeal squamous cell carcinoma by down-regulating hexokinase-2.
Hui L; Zhang J; Guo X
Biomed Pharmacother; 2018 Jul; 103():1194-1201. PubMed ID: 29864898
[TBL] [Abstract][Full Text] [Related]
12. HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection.
Tan VP; Miyamoto S
Autophagy; 2015; 11(6):963-4. PubMed ID: 26075878
[TBL] [Abstract][Full Text] [Related]
13. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.
Patra KC; Wang Q; Bhaskar PT; Miller L; Wang Z; Wheaton W; Chandel N; Laakso M; Muller WJ; Allen EL; Jha AK; Smolen GA; Clasquin MF; Robey B; Hay N
Cancer Cell; 2013 Aug; 24(2):213-228. PubMed ID: 23911236
[TBL] [Abstract][Full Text] [Related]
14. Hexokinase 2 in Cancer: A Prima Donna Playing Multiple Characters.
Ciscato F; Ferrone L; Masgras I; Laquatra C; Rasola A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946854
[TBL] [Abstract][Full Text] [Related]
15. The decrease of glycolytic enzyme hexokinase 1 accelerates tumor malignancy via deregulating energy metabolism but sensitizes cancer cells to 2-deoxyglucose inhibition.
Tseng PL; Chen CW; Hu KH; Cheng HC; Lin YH; Tsai WH; Cheng TJ; Wu WH; Yeh CW; Lin CC; Tsai HJ; Chang HC; Chuang JH; Shan YS; Chang WT
Oncotarget; 2018 Apr; 9(27):18949-18969. PubMed ID: 29721175
[TBL] [Abstract][Full Text] [Related]
16. Glycolysis back in the limelight: systemic targeting of HK2 blocks tumor growth.
Ros S; Schulze A
Cancer Discov; 2013 Oct; 3(10):1105-7. PubMed ID: 24124231
[TBL] [Abstract][Full Text] [Related]
17. Loss of hexokinase 1 sensitizes ovarian cancer to high-dose metformin.
Šimčíková D; Gardáš D; Hložková K; Hruda M; Žáček P; Rob L; Heneberg P
Cancer Metab; 2021 Dec; 9(1):41. PubMed ID: 34895333
[TBL] [Abstract][Full Text] [Related]
18. A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers.
Xu S; Catapang A; Braas D; Stiles L; Doh HM; Lee JT; Graeber TG; Damoiseaux R; Shirihai O; Herschman HR
Cancer Metab; 2018; 6():7. PubMed ID: 29988332
[TBL] [Abstract][Full Text] [Related]
19. Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway.
Wu J; Zhang X; Wang Y; Sun Q; Chen M; Liu S; Zou X
Oncol Rep; 2018 Mar; 39(3):1181-1190. PubMed ID: 29286170
[TBL] [Abstract][Full Text] [Related]
20. INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells.
Min JW; Kim KI; Kim HA; Kim EK; Noh WC; Jeon HB; Cho DH; Oh JS; Park IC; Hwang SG; Kim JS
Biochem Biophys Res Commun; 2013 Oct; 440(1):137-42. PubMed ID: 24051093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
